about
Profile of bevacizumab and its potential in the treatment of cervical cancerMechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiformeAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesNitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Expression of hypoxia-inducible factor-1α and vascular density in mammary adenomas and adenocarcinomas in bitches.Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report.Monoclonal antibodies against autocrine motility factor suppress gastric cancer.Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapyPulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo.Bevacizumab plus ipilimumab in patients with metastatic melanoma.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.Molecular evidence of cryptotanshinone for treatment and prevention of human cancerMolecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyInfluence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report.Therapeutic application of monoclonal antibodies in cancer: advances and challenges.Endoglin for tumor imaging and targeted cancer therapy.Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).New approaches to selectively target cancer-associated matrix metalloproteinase activity.Combination cancer immunotherapies tailored to the tumour microenvironment.Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer TherapyPhase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
P2860
Q26774168-5AB2478B-3820-4830-A300-469BE14DCA6BQ26824557-59FA9BC8-017A-480D-A297-2DA2DCCEFE2DQ26826817-1DC77ACD-44C4-4241-8F1B-41F21A5DB0D9Q30431810-363B3587-FAB6-4CA4-96F0-DBF022679B7BQ33438641-7D3C960A-B492-4D3D-B753-F224CFA2A66DQ33591698-FAB75DD4-9A14-4893-B2EF-7FDB8EC572F9Q33684824-CB54D8E3-8B54-4F00-A181-B000315D9121Q33751147-AA31443C-630C-409F-B652-004A11BDB611Q34005213-F5FBBC3A-8FFB-445C-AE39-0F3C6758FCBCQ34404209-136EA4A4-B831-458E-A183-212F0F48A91FQ34947216-9DFF4F04-025A-4928-BE53-6BBFC2DACD03Q35012765-F2E45054-3E7D-4ED8-ACA9-021D8745060CQ35079683-7EC0F3FB-D7DD-4D9D-A1EE-F751BB32CB7BQ35407573-CDEA01BD-70D0-48CE-8977-F0F4452F5A44Q35895339-1AF3173E-8C3F-4758-B146-9FDD66424AC1Q36413742-0D29708D-8C6C-44BE-9350-17C85F0CA2E5Q36763730-4C42FEF4-AB67-416F-88A5-B7F370F79BD0Q37347532-B616F112-CE4F-45F7-A8E4-09D3F048A889Q37390315-A479A1FE-7E76-404A-B783-0782CFD34679Q38057179-77D14CB2-BFD2-40C1-A300-29E28348C8DBQ38074721-0250D1DB-9FDE-4CDE-A7E5-23F788B288B1Q38078259-AD6CBF84-E054-4DA0-B907-2B16A34C5B7AQ38261141-C87C2D0E-D226-4DDD-984C-32BC86F8C590Q38645178-BF2AA0FD-8A79-45D8-86AD-D1F5F2AA7837Q39521987-D1234F94-D3E3-4C97-B058-5B2F1BAFF2A1Q40041609-73C8682A-0EFB-4E97-96F9-BA34FD05C067Q41574359-007D9F76-5BDE-4061-874B-2150C30AA06DQ45304925-06C1D735-9175-48F6-B1D0-040208617A2F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bevacizumab: overview of the literature.
@en
type
label
Bevacizumab: overview of the literature.
@en
prefLabel
Bevacizumab: overview of the literature.
@en
P2093
P2860
P356
P1476
Bevacizumab: overview of the literature.
@en
P2093
Jorge Sabbaga
Maria Ignez Braghiroli
Paulo M Hoff
P2860
P304
P356
10.1586/ERA.12.13
P577
2012-05-01T00:00:00Z